Edition:
United States

Profile: Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,450.00INR
23 Feb 2017
Change (% chg)

Rs-2.80 (-0.19%)
Prev Close
Rs1,452.80
Open
Rs1,450.00
Day's High
Rs1,465.65
Day's Low
Rs1,444.85
Volume
1,225,360
Avg. Vol
947,015
52-wk High
Rs1,874.60
52-wk Low
Rs1,280.00

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. The Company also offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas. The Company along with its subsidiaries has manufacturing locations spread across India, Japan, the United States, Mexico and Brazil. It has a pipeline of biosimilars addressing therapies, such as oncology, anti-inflammatory, anti-viral, rheumatoid arthritis, endocrinology, diabetes, ophthalmology and women's health. The Company's products include Antara, Methergine, Methylphenidate, Glumetza, Gluconorm, Tonact, Rcinex and Ramistar, among others.

Company Address

Lupin Ltd

B/4 Laxmi Towers
, Bandra Kurla Complex, Bandra (
MUMBAI     400051
P: +9122.66402222
F: +9122.66402130

Company Web Links